Randomized placebo‐controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Testosterone deficiency is associated with significant morbidity, and androgen replacement in overt hypogonadism is clearly beneficial. However, there are few data concerning the response to therapy in young men with mild testosterone deficiency. DESIGN AND PATIENTS We have identified a cohort of 35 men, mean age 40·9 years, with mild Leydig cell dysfunction, defined by a raised LH level (LH ≥ 8 IU/l) and a testosterone level in the lower half of the normal range or frankly subnormal (testosterone < 20 nmol/l), following treatment with cytotoxic chemotherapy for malignancy. Patients were assigned randomly to 12 months treatment with transdermal testosterone (n = 16) (Andropatch 2·5 mg patches, 1–2 patches per day) or placebo patches (n = 19) in a single blinded manner. MEASUREMENTS Measurements of bone mineral density (BMD) and body composition were performed at baseline, 6 months and 12 months using single and dual energy X‐ray absorptiometry (SXA, DXA). In addition, spinal BMD was assessed at baseline and 12 months by quantitative CT (QCT). Subjects were reviewed at 3‐monthly intervals; at each visit blood was taken for measurement of testosterone, SHBG, LH, FSH, oestradiol, lipids and IGF‐1 and patients completed three questionnaires which assessed energy levels, mood and sexual function. RESULTS Total testosterone and calculated free testosterone increased significantly in the testosterone‐treated group compared with the placebo‐treated group (13·3 nmol/l and 342·9 pmol/l at baseline compared with 17·3 nmol/l and 454·8 pmol/l during the study period in the testosterone‐treated group; P = 0·05 and P = 0·02, respectively). LH was suppressed into the normal range in 15 of the 16 testosterone‐treated men and mean LH significantly reduced from 11·1 IU/l at baseline to 6·8 IU/l during the study. There was no significant change in BMD at the hip, spine or forearm and no change in fat or lean body mass. There was a significant reduction in physical fatigue in the testosterone‐treated group compared with the placebo‐treated group (P = 0·008) and a borderline improvement in activity score (P = 0·05). There were no significant effects of treatment on mood or sexual function. Neither oestradiol nor IGF‐1 levels differed between the two groups during the study. There was no significant change in mean total cholesterol, HDL cholesterol or triglyceride levels, but there was a small, but significant reduction in LDL cholesterol levels in the testosterone‐treated group compared with the placebo group (P = 0·02). CONCLUSIONS These results suggest that testosterone therapy in young men with raised LH levels and low/normal testosterone levels does not result in significant changes in BMD, body composition, lipids or quality of life, apart from a reduction in physical fatigue and a small reduction in LDL cholesterol. This implies that mild hypogonadism defined on this basis is not of clinical importance in the majority of men, and that androgen replacement cannot be recommended for routine use in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · cited 6×
“Fax: 0161 4463772; E-mail: Mmassey@picr.man.ac.uk 1986; Finkelstein et al., 1987), changes in body composition (Katznelson et al., 1996; Katznelson et al., 1998), increased fatigue, sexual dysfunction and alterations in mood (Burris et al., 1992).”
BackgroundInfluentialEffects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559 · cited 5×
“…there were no changes in lean or fat mass. Studies of testosterone replacement in frankly hypogonadal males have shown increases in bone density and muscle mass, and reductions in body fat (Brodsky et al., 1996; Katznelson et al., 1996; Behre et al., 1997; Bhasin et al., 1997; Leifke et al., 1998).”
BackgroundInfluentialTestosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men1
Bhasin, S., Storer, T. W., Berman, N., Yarasheski, K. E., Clevenger, B., Phillips, J., Lee, W. P., Bunnell, T. J., & Casaburi, R. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3733 · Cited by 522
Screening for Adjustment Disorders and Major Depressive Disorders in Cancer In-Patients
Razavi, D., Delvaux, N., Farvacques, C., & Robaye, E. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.156.1.79 · Cited by 514 · cited 1×
“This is a 14-item questionnaire which has been well validated as a tool for identifying abnormal mood states in cancer patients (Razavi et al., 1990; Ibbotson et al., 1994).”
MethodBrodsky, I. G., Balagopal, P., & Nair, K. S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855787 · Cited by 444 · cited 4×
“Testosterone replacement in frankly hypogonadal males increases bone density and muscle mass, reduces body fat (Brodsky et al., 1996; Katznelson et al., 1996; Behre et al., 1997; Bhasin et al., 1997; Leifke et al., 1998) and improves mood, sexual function and energy levels (Arver et al.”
BackgroundInfluentialScreening for anxiety and depression in cancer patients: the effects of disease and treatment
Ibbotson, T., Maguire, P., Selby, P., Priestman, T., & Wallace, L. (1994) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80015-2 · Cited by 421 · cited 1×
“This is a 14-item questionnaire which has been well validated as a tool for identifying abnormal mood states in cancer patients (Razavi et al., 1990; Ibbotson et al., 1994).”
MethodBURRIS, A. S., BANKS, S. M., CARTER, C. S., DAVIDSON, J. M., & SHERINS, R. J. (1992) · Journal of Andrology · doi:10.1002/j.1939-4640.1992.tb00319.x · Cited by 259 · cited 2×
“, 1998), increased fatigue, sexual dysfunction and alterations in mood (Burris et al., 1992).”
BackgroundEffect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men
Zgliczynski, S., Ossowski, M., Slowinska-Srzednicka, J., Brzezinska, A., Zgliczynski, W., Soszynski, P., Chotkowska, E., Srzednicki, M., & Sadowski, Z. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05673-4 · Cited by 167
Cited by
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
“Boyanov, 2003 (33) 0% 3 NR N N N NR Brockenbrough, 2006 (34) 45, 42, 48% 6 Probably Y Y Y NR Includes FP Cavallini, 2004 (35) 13% 12 Probably Y Y Y NR NR Chiang, 2007 (18) 10, 0, 20% 3 NR Y Y NR Includes FP Clague, 1999 (36) NR 3 Probably Y Y Y NR Includes FP Coodley, 1997 (37) 10% 3 NR Y Y NR Includes FP Copenhagen S…”
Engelke, K., Adams, J. E., Armbrecht, G., Augat, P., Bogado, C. E., Bouxsein, M. L., Felsenberg, D., Ito, M., Prevrhal, S., Hans, D. B., et al. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.010 · Cited by 617
Self-citationAndrogens and Coronary Artery Disease
Wu, F. C. W., & von Eckardstein, A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0025 · Cited by 592
Wittert, G. A., Chapman, I. M., Haren, M. T., Mackintosh, S., Coates, P., & Morley, J. E. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.7.m618 · Cited by 345
Metadata
- Authors
- Howell, S. J., Radford, J. A., Adams, J. E., Smets, E. M. A., Warburton, R., & Shalet, S. M.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2001-09
- Volume
- 55
- Issue
- 3
- Pages
- 315-324
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2109964083
- Cited by
- 116
- References
- 12
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized placebo‐controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. https://app.cochat.ai/papers/10.1046/j.1365-2265.2001.01297.x
- The paper
- Howell, S. J., Radford, J. A., Adams, J. E., Smets, E. M. A., Warburton, R., & Shalet, S. M. (2001). Randomized placebo‐controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2001.01297.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.